Accelerating the development and future availability of HIV-1 vaccines: Why, when, where, and how?

Lancet

Volumn 355, Issue 9220, 2000, Pages 2061-2066

  Esparza, José ^a   Bhamarapravati, Natth ^b  

^a WORLD HEALTH ORGANIZATION   (Switzerland)

^b MAHIDOL UNIVERSITY   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

DNA VACCINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE;

CLINICAL TRIAL; DRUG EFFICACY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; META ANALYSIS; PRIORITY JOURNAL; REVIEW; THAILAND; UNITED STATES;

EID: 0034631503     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(00)02360-6     Document Type: Review

References (41)

1. UNAIDS, WHO. AIDS epidemic update: December, 1999 (document UNAIDS/99.53E). Geneva: WHO, 1999.
2. Esparza J, Mpunju-Shumbusho WK. Issues involved with HIV vaccines. In: HIV/AIDS in the Commonwealth. London: Kensington Publications Limited (in press).
3. Esparza J., Heyward W.L., Osmanov S. HIV vaccine development. from basic research to human trials AIDS. 10(suppl A):1996;123-132.
4. Osmanov S., Esparza J. Development and evaluation of preventive HIV-1 vaccines. Saksena N. Human immunodeficiency viruses: biology, immunology and molecular biology. 1998;501-505 Medical Systems, Genoa.
5. Girard M., Habel A., Chanel C. New prospects for the development of a vaccine against human immunodeficiency virus type 1. An overview. C R Acad Sci III. 322:1999;959-966.
6. Nitayaphan S., Brown A.E. Preventive HIV vaccine development in Thailand. AIDS. 12(suppl B):1998;155-161.
7. Nitayaphan S., Khambooruang C., Sirisophana N.et al. A phase I/II of HIV SF2 gp120/MF59 vaccine in seronegative Thais. Vaccine. 18:2000;1448-1455.
8. Tartaglia J., Excler J.L., El Habib R.et al. Canarypox virus-based vaccines. prime-boost strategies to induce cell-mediated and humoral immunity against HIV AIDS Res Hum Retroviruses. 14(suppl 3):1998;291-298.
9. Evans T.G., Keefer M.C., Weinhold K.J.et al. A canarypox vaccine expressing multiple human immunodeficiency virus type 1 genes given alone or with rgp120 elicits broad and durable CD8+ cytotoxic T lymphocyte responses in seronegative volunteers. J Infect Dis. 180:1999;290-308.
10. Boyer J.D., Kim J., Ugen K.et al. HIV-1 DNA vaccines and chemokines. Vaccine. 17(suppl 2):1999;53-64.
11. Boyer J.D., Cohen A.D., Vogt S.et al. Vaccination of seronegative volunteers with a human immunodeficiency virus type 1 env/rev DNA vaccine induces antigen-specific proliferation and lymphocyte production of β-chemokines. J Infect Dis. 181:2000;476-483.
12. Francis D.P., Gregory T., McElrath M.J.et al. Advancing AIDSVAX to phase 3. Safety, immunogencity, and plans for phase 3. AIDS Res Hum retroviruses. 14(suppl 3):1998;325-331.
13. Berman P.W., Huang W., Riddle L.et al. Development of bivalent (B/E) vaccines able to neutralize CCR5-dependent viruses from the United States and Thailand. Virology. 265:1999;1-9.
14. MacQueen K.M., Vanichseni S., Kitayaporn D.et al. Willingness of injection drug users to participate in an HIV vaccine efficacy trial in Bangkok, Thailand. J Acquir Immune Defic Syndr. 21:1999;243-251.
15. Rida W., Fast P., Hoff R., Fleming T. Intermediate-size trials for the evaluation of HIV vaccine candidates. a workshop summary J Acquir Immune Defic Syndr Hum Retrovirol. 16:1997;195-203.
16. Datta S., Halloran M.E., Longini I.M. Jr. Augmented HIV vaccine trial design for estimating reduction in infectiousness and protective efficacy. Stat Med. 17:1998;185-200.
17. Boily M.C., Masse B.R., Desai K., Alary M., Anderson R.M. Some important issues in the planning of phase III HIV vaccine efficacy trials. Vaccine. 17:1999;989-1004.
18. Hilleman M.R. The business of science and the science of business in the quest for an AIDS vaccine. Vaccine. 17:1999;1211-1222.
19. Heeney J.L., Beverly P., McMichael A.et al. Immune correlates of protection from HIV and AIDS. more answers but yet more questions Immunol Today. 20:1999;247-251.
20. Mascola J.R., Snyder S.W., Weislow O.S.et al. Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. J Infect Dis. 173:1996;340-348.
21. Bolognesi D.P., Matthews T.J. HIV vaccines. Viral envelope fails to deliver? Nature. 391:1998;638-639.
22. Zolla-Pazner S., Xu S., Burda S., Duliege A.M., Excler J.L., Clements-Mann M.L. Neutralization of syncytium-inducing primary isolates by sera from human immunodeficiency virus (HIV)-uninfected recipients of candidate vaccines. J Infect Dis. 178:1998;1502-1506.
23. LaCasse R.A., Follis K.E., Trahey M., Scarborough J.D., Littman D.R., Nunberg J.H. Fusion-competent vaccines. broad neutralization of primary isolates of HIV Science. 283:1999;357-362.
24. Hanke T., McMichael A. Pre-clinical development of a multi-CTL epitope-based DNA prime MVA boost vaccine for AIDS. Immunol Lett. 66:1999;177-181.
25. Davis N.L., Caley I.J., Brown K.W.et al. Vaccination of macaques against pathogenic simian immunodeficiency virus with Venezuelan equine encephalitis virus replicon particles. J Virol. 74:2000;371-378.
26. Nathanson N., Mathieson B.J. Towards an AIDS vaccine. the role of nonhuman primates J Med Primatol. 28:1999;146-153.
27. Berman P.W., Murthy K.K., Wrin T.et al. Protection of MN-rgp120-immunized chimpanzees from heterologous infection with a primary isolate of human immunodeficiency virus type 1. J Infect Dis. 173:1996;52-59.
28. Rowland-Jones S., Dong T., Krausa P.et al. The role of cytotoxic T-cells in HIV infection. Dev Biol Stand. 92:1998;209-214.
29. Clements-Mann M.L. Lessons for AIDS vaccine development from non-AIDS vaccines. AIDS Res Hum Retroviruses. 14(suppl 3):1998;197-203.
30. Brown A.E., McNeil J.G. HIV vaccine development. a subtype E-specific strategy Southeast Asian J Trop Med Public Health. 29:1998;377-382.
31. Van der Groen G., Nyambi P.N., Beirnaert E.et al. Genetic variation of HIV type 1. relevance of interclade variation to vaccine development AIDS Res Hum Retroviruses. 14(suppl 3):1998;211-221.
32. Ferrari G., Humphrey W., McElrath M.J.et al. Clade B-based HIV-1 vaccines elicit cross-clade cytotoxic T lymphocyte reactivities in uninfected volunteers. Proc Natl Acad Sci USA. 94:1997;1396-1401.
33. Esparza J., Osmanov S., Kallings L.O., Wigzell H. Planning for HIV vaccine trials. the World Health Organization perspective AIDS. 5(suppl 2):1991;159-163.
34. Bloom B.R. The highest attainable standard. ethical issues in AIDS vaccines Science. 279:1998;186-188.
35. Guenter D., Esparza J., Macklin R. Ethical considerations in international HIV vaccine trials. summary of a consultative process conducted by the Joint United Nations Programme on HIV/AIDS (UNAIDS) J Med Ethics. 26:2000;37-43.
36. UNAIDS. Ethical considerations in HIV preventive vaccine research (document UNAIDS/00.07E). Geneva: WHO, 2000 (available online at www.unaids.org/publications/documents/vaccines/vaccines/ethicsresearch.doc ).
37. AIDS vaccine research in Asia: needs and opportunities. Report from a UNAIDS/WHO/NIID meeting, Tokyo, 28-30 October 1998. AIDS. 13:1999;1-13.
38. Mahoney R.T., Maynard J.E. The introduction of new vaccines into developing countries. Vaccine. 17:1999;646-652.
39. Anderson R.M., Garnett G.P. Low-efficacy HIV vaccines. potential for community-based intervention programmes Lancet. 348:1996;1010-1013.
40. Vermund S.H. Rationale for the testing and use of a partially effective HIV vaccine. AIDS Res Hum Retroviruses. 14(suppl 3):1998;321-323.
41. Goldenthal K.L., Vaillancourt J.M., Geber A., Lucey D.R. Preventive HIV type 1 vaccine clinical trials. a regulatory perspective AIDS Res Hum Retroviruses. 14(suppl 3):1998;333-340.